Human plasma derived hepatitis B vaccine: Kenyan experience

Objective: To determine the efficacy and safety of hepaccine B. Design: Vaccination on first-come-first-served basis. Setting: Kenya Medical Research Institute (KEMRI) staff and families at Nai robi, Kenya. Participants: A total of 107 vaccinees aged 0-10 years and 10 years and abo ve. Main outcome: Antibody to hepatitis B surface antigen (anti HBs) checked on e month after the third dose of the vaccine. Results: Ninety seven per cent of the vaccinees developed antiHBs, Side eff ects were few in the form of soreness at site of injection and headache. Conclusion: Hepaccine B produced good immune response in vaccinees with min imal side effects.